Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial

Journal of the American College of Cardiology

Volumn 67, Issue 10, 2016, Pages 1145-1154

  Storey, Robert F ^a   Angiolillo, Dominick J ^b   Bonaca, Marc P ^c   Thomas, Mark R ^a   Judge, Heather M ^a   Rollini, Fabiana ^b   Franchi, Francesco ^b   Ahsan, Arif J ^d   Bhatt, Deepak L ^c   Kuder, Julia F ^c   Steg, Philippe Gabriel ^e   Cohen, Marc ^f   Muthusamy, Rangasamy ^g   Braunwald, Eugene ^c   Sabatine, Marc S ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e INSERM   (France)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g Rotherham NHS Foundation Trust   (United Kingdom)

Author keywords

coronary artery disease; Key Words aspirin; P2Y12 receptor

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE B2; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LIGHT TRANSMITTANCE AGGREGOMETRY; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PLATELET INHIBITION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; MYOCARDIAL INFARCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; TIME FACTOR; TREATMENT OUTCOME;

ADENOSINE; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84961221540     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.12.062     Document Type: Article

References (30)

1. F. Franchi, and D.J. Angiolillo Novel antiplatelet agents in acute coronary syndrome Nat Rev Cardiol 12 2015 30 47
2. P.A. Gurbel, K.P. Bliden, K. Butler, and et al. Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study Circulation 120 2009 2577 2585
3. R.F. Storey, S. Husted, R.A. Harrington, and et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 50 2007 1852 1856
4. R.F. Storey, D. Angiolillo, S. Patil, and et al. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy J Am Coll Cardiol 56 2010 1456 1462
5. L. Wallentin, R.C. Becker, A. Budaj, et al. for the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
6. E.A. Amsterdam, N.K. Wenger, R.G. Brindis, and et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 64 2014 e139 e228
7. M. Roffi, C. Patrono, J.-P. Collet, and et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 37 2016 267 315
8. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
9. P.G. Steg, S.K. James, D. Atar, and et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
10. M.P. Bonaca, D.L. Bhatt, E. Braunwald, and et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54 (PEGASUS-TIMI 54) trial Am Heart J 167 2014 437 444.e5
11. M.P. Bonaca, D.L. Bhatt, M. Cohen, et al. for the PEGASUS-TIMI 54 Steering Committee and Investigators Long-term use of ticagrelor in patients with prior myocardial infarction N Engl J Med 372 2015 1791 1800
12. F. Franchi, F. Rollini, J.R. Cho, and et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of a prospective randomized pharmacokinetic and pharmacodynamic investigation J Am Coll Cardiol Intv 8 2015 1457 1469
13. U.S. Tantry, L. Bonello, D. Aradi, et al. for the Working Group on On-Treatment Platelet Reactivity Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
14. M.J. Price, S. Endemann, R.R. Gollapudi, and et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
15. G.W. Stone, B. Witzenbichler, G. Weisz, et al. for the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study Lancet 382 2013 614 623
16. D.J. Angiolillo, S.B. Shoemaker, B. Desai, and et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease. Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study Circulation 115 2007 708 716
17. P.A. Gurbel, M.J. Antonino, K.P. Bliden, and et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target Platelets 19 2008 595 604
18. L. Bonello, U.S. Tantry, R. Marcucci, et al. for the Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
19. L. Bonello, F. Paganelli, M. Arpin-Bornet, and et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events J Thromb Haemost 5 2007 1630 1636
20. H.L. Nielsen, S.D. Kristensen, S.S. Thygesen, and et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry Thromb Res 123 2008 267 273
21. N. Blais, C. Pharand, M. Lordkipanidzé, and et al. Response to aspirin in healthy individuals-cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2 Thromb Haemost 102 2009 404 411
22. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, and et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961 965
23. J. DiChiara, K.P. Bliden, U.S. Tantry, and et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the Aspirin-Induced Platelet Effect (ASPECT) Study Diabetes 56 2007 3014 3019
24. S. Husted, H. Emanuelsson, S. Heptinstall, and et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
25. C.P. Cannon, S. Husted, R.A. Harrington, et al. for the DISPERSE-2 Investigators Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial J Am Coll Cardiol 50 2007 1844 1851
26. R.F. Storey, K. Bliden, S.B. Patil, et al. for the ONSET/OFFSET Investigators Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel or placebo in the ONSET/OFFSET Study J Am Coll Cardiol 56 2010 185 193
27. R.F. Storey, R.C. Becker, R.A. Harrington, and et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes Eur Heart J 32 2011 2945 2953
28. American College of Cardiology. FDA Expands Approval for Heart Attack Drug. 2015. Available at: Http://www.acc.org/latest-in-cardiology/articles/2015/09/04/11/55/fda-expands-approval-for-heart-attack-drug?w-nav=LC. Accessed January 4, 2016.
29. S. Nylander, E.A. Femia, M. Scavone, and et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism J Thromb Haemost 11 2013 1867 1876
30. L. Bonello, M. Laine, N. Kipson, and et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome J Am Coll Cardiol 63 2014 872 877